Opana IR Pediatric Labeling Supplement Faces US FDA Panel Review

 
• By Sue Sutter
  
Children-drug-danger
Pediatric labeling for opioids will be the AdComm's focus. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers